SEARCH FILTERS
Time filter
Source Type

News Article | April 25, 2017
Site: marketersmedia.com

Celiac Disease Pipeline Market Review, H1 2017 report provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).This report find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).Pune, India - April 25, 2017 /MarketersMedia/ — ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Browse 35 Tables and Figures, 13 Company Profiles, spread across 82 pages available @ http://www.reportsnreports.com/contacts/discount.aspx?name=958314. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogrens syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. Celiac Disease - Companies Involved in Therapeutics Development Amgen Inc, Amyra Biotech AG, Calypso Biotech SA, Circle33 LLC, enGene Inc, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp, Sanofi, Takeda Pharmaceutical Company Ltd, Zedira GmbH Report Highlights Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Order a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=958314. Scope of the report: - The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal) List of Tables Number of Products under Development for Celiac Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Celiac Disease - Pipeline by Amgen Inc, H1 2017 Celiac Disease - Pipeline by Amyra Biotech AG, H1 2017 Celiac Disease - Pipeline by Calypso Biotech SA, H1 2017 Celiac Disease - Pipeline by Circle33 LLC, H1 2017 Celiac Disease - Pipeline by enGene Inc, H1 2017 About Us ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Contact Info:Name: Ritesh TiwariEmail: sales@reportsandreports.comOrganization: ReportsnReports.comAddress: Magarpatta City, Pune, Maharashtra, IndiaPhone: +1-888-391-5441Source URL: http://marketersmedia.com/h1-2017-celiac-disease-gastrointestinal-pipeline-market-landscape-review-report/189602For more information, please visit http://www.reportsnreports.com/reports/958314-celiac-disease-pipeline-review-h1-2017.htmlSource: MarketersMediaRelease ID: 189602


Stieler M.,University of Marburg | Weber J.,Zedira GmbH | Hils M.,Zedira GmbH | Kolb P.,University of Marburg | And 4 more authors.
Angewandte Chemie - International Edition | Year: 2013

On active duty: The available drugs for cardiovascular diseases can promote blood clotting but can also lead to life-threatening bleeding episodes. A promising target for the development of safer alternatives is the transglutaminase Factor XIII (FXIII), the active structure of which is presented. The binding and coordination of three calcium ions induce major domain movements in the enzyme upon activation. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Rizzi S.C.,Queensland University of Technology | Rizzi S.C.,QGel SA | Upton Z.,Queensland University of Technology | Bott K.,Zedira GmbH | Dargaville T.R.,Queensland University of Technology
Expert Review of Medical Devices | Year: 2010

Successful repair of wounds and tissues remains a major healthcare and biomedical challenge in the 21st Century. In particular, chronic wounds often lead to loss of functional ability, increased pain and decreased quality of life, and can be a burden on carers and health-system resources. Advanced healing therapies employing biological dressings, skin substitutes, growth factor-based therapies and synthetic acellular matrices, all of which aim to correct irregular and dysfunctional cellular pathways present in chronic wounds, are becoming more popular. This review focuses on recent advances in biologically inspired devices for wound healing and includes a commentary on the challenges facing the regulatory governance of such products. © 2010 Expert Reviews Ltd.


The invention relates to pyridinone derivatives of general formula (I) as inhibitors of tissue transglutaminase, to methods for producing the pyridinone derivatives, to pharmaceutical compositions containing said pyridinone derivatives and to their use for the prophylaxis and treatment of diseases associated with tissue transglutaminase.


Patent
Zedira GmbH | Date: 2014-06-18

The present invention relates to crystal forms of blood coagulation factor XIIIa, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and / or design of inhibitors of blood coagulation factor XIIIa activity and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit blood coagulation factor XIIIa.


Patent
Zedira GmbH | Date: 2013-12-10

The present invention relates to crystal forms of blood coagulation factor XIIIa, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and/or design of inhibitors of blood coagulation factor XIIIa activity and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit blood coagulation factor XIIIa.


Trademark
Zedira GmbH | Date: 2010-02-23

Chemical and biochemical products, namely, chemicals, chemical preparations, and biochemical preparations for industrial or scientific purposes; chemical or biochemical products for medical science for application in or to the human and animal body, namely, chemical reagents. Pharmaceuticals, pharmaceutical and veterinary products as well as preparations for health care, namely, for the treatment and prophylaxis of celiac disease, autoimmune diseases, food intolerances, bowel diseases, irritable bowel, fibroses, scar formation, hypertrophic scars, scleroderma, diabetic nephropathies, liver fibrosis, cirrhosis, lung fibrosis, arteriosclerosis, cancer, thrombolysis, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimers disease, Huntingtons disease, Parkinsons disease, cataract, infestation with microorganisms, infections or candidoses; chemical and biochemical products for healing purposes and health care, namely, chemical and biochemical preparations for sanitary use; chemical and biochemical products, namely, chemical and biochemical reagents for human and veterinary medical purposes; dietetic products for medical purposes and health care, namely, dietetic foods and sugar for medical use; dietetic products for human and veterinary medical purposes, namely, dietary supplements; dietary supplements for medical purposes; disinfectants for sanitary purposes; preparations for exterminating noxious animals; diagnostic preparations for medical purposes; X-ray contrast agents for medical purposes; detergents for medical purposes. Contract medical research; conducting research and development projects in the fields of medicine, pharmacy, pharmacology, biochemistry or medical technology on behalf of third parties; commissioned performance of clinical trials and clinical studies for medical research purposes; commissioned assessment of the performance of clinical trials and studies for medical research purposes; biochemical laboratories; chemical analysis laboratories; medical laboratories and bacteriological research laboratories.


Trademark
Zedira GmbH | Date: 2011-03-08

Chemical and biochemical products, namely, chemicals, chemical preparations, biochemical preparations for industrial or scientific purposes. Medicines for the treatment of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimers disease, Huntingtons diseases, Parkinsons disease, cataracts, affection by microorganisms, infections or candidiasis; pharmaceutical and veterinary medical products, namely, preparations for healthcare for the treatment of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimers disease, Huntingtons diseases, Parkinsons disease, cataracts, affection by microorganisms, infections or candidiasis; preparations or pharmaceuticals, namely, for the treatment and prophylaxis of celiac diseases, autoimmune diseases, food intolerances, intestinal diseases, irritable bowel syndrome, fibrosis, scarring, hypertrophic scars, scleroderma, diabetic nephropathy, hepatic fibrosis, cirrhosis, pulmonary fibrosis, atherosclerosis, cancer, thrombolytic therapy, acne, skin aging, psoriasis, neurodegenerative diseases, Alzheimers disease, Huntingtons disease, Parkinsons disease, cataracts, bacterial or yeast infection, infections, or candidiasis; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for medical purposes; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for healthcare; chemical and biochemical products, namely, chemical preparations in the nature of chemical reagents and biochemical preparations for human and veterinary medical use; dietetic products, namely, dietary supplements, dietetic foods adapted for medical use; dietetic products, namely, dietary supplements, dietetic foods adapted for healthcare; dietetic products, namely, dietary supplements, dietetic foods adapted for human and veterinary medical use; dietary supplements for medical purposes; disinfectants for medical instruments, for hygienic purposes, for sanitary purposes; preparations for destroying vermin; chemical and biochemical products for medical science for use in or on the human or animal body, namely, biochemical preparations and chemical reagents; diagnostic agent for medical purposes; X-ray contrast agent for medical purposes; germicidal detergents for medical purposes. Commissioned research in the field of medical research, medical devices and biological research; conducting research and development work in the medical, pharmaceutical, pharmacological, biochemical and/or medicine technological area on behalf of third parties; commissioned execution of clinical trials and clinical studies in the field of medical and scientific research; commissioned assessment of scientific projects in the field of quality assessment and evaluation, commissioned evaluation of clinical trials and studies in the field of quality assessment and evaluation; services of a biochemical laboratory; services of an analytical laboratory in the field of medical, biological and chemical.


The present invention relates to the diagnosis of disorders or dysfunctions characterized by autoimmune responses to the enzyme class of transglutaminases. The present invention provides a novel open structure of the transglutaminases in a stabilized form which renders new epitopes accessible for antibody-binding.


Trademark
Zedira GmbH | Date: 2011-02-22

Chemicals and biochemicals used in industry and science, chemicals and biochemicals for apheresis. Medicines, pharmaceutical, veterinary and sanitary preparations for the treatment, prophylaxis and diagnosis of diseases; pharmaceutical preparations in particular for the treatment, prophylaxis and diagnosis of autoimmune disorders, gluten-sensitive autoimmune disorders, coeliac disease, dermatitis herpetiformis, Duhrings disease, gluten-sensitive ataxia, food incompatibilities, intestinal disorders, irritable bowel syndrome, fibrosis, scar formation, hypertrophic scars, scleroderma, diabetic nephropathies, liver fibrosis, cirrhosis, lung fibrosis, arteriosclerosis, cancer, thrombolysis, acne, skin ageing, psoriasis, neurodegenerative disorders, Alzheimers disease, Huntingtons disease, Parkinsons disease, cataracts, affliction by micro-organisms, infections or candidosis; chemical and biochemical preparations for medicinal purposes, chemical and biochemical preparations for sanitary purposes, chemical and biochemical preparations for medical and veterinary purposes, all the aforementioned for the treatment, prophylaxis and diagnosis of autoimmune disorders, gluten-sensitive autoimmune disorders, coeliac disease, dermatitis herpetiformis, Duhrings disease, gluten-sensitive ataxia, food incompatibilities, intestinal disorders, irritable bowel syndrome, fibrosis, scar formation, hypertrophic scars, scleroderma, diabetic nephropathies, liver fibrosis, cirrhosis, lung fibrosis, arteriosclerosis, cancer, thrombolysis, acne, skin ageing, psoriasis, neurodegenerative disorders, Alzheimers disease, Huntingtons disease, Parkinsons disease, cataracts, affliction by micro-organisms, infections or candidosis; dietetic foods adapted for medical use and dietetic foods for medical and veterinary purposes; food supplements for medical purposes; disinfectants for sanitary purposes; preparations for destroying vermin; chemical and biochemical preparations for use in medical science for use in or on human and/or animal bodies for the treatment, prophylaxis and diagnosis of autoimmune disorders, gluten-sensitive autoimmune disorders, coeliac disease, dermatitis herpetiformis, Duhrings disease, gluten-sensitive ataxia, food incompatibilities, intestinal disorders, irritable bowel syndrome, fibrosis, scar formation, hypertrophic scars, scleroderma, diabetic nephropathies, liver fibrosis, cirrhosis, lung fibrosis, arteriosclerosis, cancer, thrombolysis, acne, skin ageing, psoriasis, neurodegenerative disorders, Alzheimers disease, Huntingtons disease, Parkinsons disease, cataracts, affliction by micro-organisms, infections or candidosis; diagnostic preparations for medical purposes; radiological contrast agents for medical purposes, germicidal detergents for medical purposes, pharmaceutical preparations for apheresis.

Loading Zedira GmbH collaborators
Loading Zedira GmbH collaborators